EP4731199A2 - Compositions comprenant des antinéoplastons et méthodes de traitement du cancer colorectal - Google Patents

Compositions comprenant des antinéoplastons et méthodes de traitement du cancer colorectal

Info

Publication number
EP4731199A2
EP4731199A2 EP24826671.0A EP24826671A EP4731199A2 EP 4731199 A2 EP4731199 A2 EP 4731199A2 EP 24826671 A EP24826671 A EP 24826671A EP 4731199 A2 EP4731199 A2 EP 4731199A2
Authority
EP
European Patent Office
Prior art keywords
disclosed
subject
cancer
treatment
colorectal cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24826671.0A
Other languages
German (de)
English (en)
Inventor
Stanislaw R. Burzynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP4731199A2 publication Critical patent/EP4731199A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions comprenant un ou plusieurs antinéoplastons et l'utilisation de ces compositions dans des méthodes destinées à traiter le cancer colorectal, à prolonger la survie d'un sujet atteint d'un cancer colorectal, et à prévenir et/ou diminuer la métastase du cancer colorectal.
EP24826671.0A 2023-06-21 2024-06-20 Compositions comprenant des antinéoplastons et méthodes de traitement du cancer colorectal Pending EP4731199A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363522375P 2023-06-21 2023-06-21
PCT/US2024/034866 WO2024263813A2 (fr) 2023-06-21 2024-06-20 Compositions comprenant des antinéoplastons et méthodes de traitement du cancer colorectal

Publications (1)

Publication Number Publication Date
EP4731199A2 true EP4731199A2 (fr) 2026-04-29

Family

ID=93936259

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24826671.0A Pending EP4731199A2 (fr) 2023-06-21 2024-06-20 Compositions comprenant des antinéoplastons et méthodes de traitement du cancer colorectal

Country Status (2)

Country Link
EP (1) EP4731199A2 (fr)
WO (1) WO2024263813A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201170940A1 (ru) * 2009-01-16 2012-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
JP2024513668A (ja) * 2021-03-05 2024-03-27 ガーダント ヘルス， インコーポレイテッド 分子応答を分析するための方法および関連する態様
ES3033720T3 (en) * 2021-05-14 2025-08-07 Universal Diagnostics S A Methods for disease detection
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment

Also Published As

Publication number Publication date
WO2024263813A3 (fr) 2025-04-10
WO2024263813A2 (fr) 2024-12-26

Similar Documents

Publication Publication Date Title
TWI654979B (zh) 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
US20230190694A1 (en) Compositions for and methods of precision cancer treatment
KR102439911B1 (ko) 제약학적 복합제제
US20180353602A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
CA2909579A1 (fr) Therapie combinee comprenant un inhibiteur de la kinase tor et du n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide pour le traitement d'un cancer
US20250387362A1 (en) Compositions for and methods of precision cancer treatment
US20220160718A1 (en) Compositions and methods of treating cancer
CN113811298B (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
US20250275955A1 (en) Use of tivozanib to treat subjects with refractory cancer
CN114302745A (zh) 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
US20250017927A1 (en) Pharmaceutical composition and use thereof
EP4731199A2 (fr) Compositions comprenant des antinéoplastons et méthodes de traitement du cancer colorectal
WO2024263801A2 (fr) Compositions comprenant des antinéoplastons et méthodes de traitement du cancer de l'ovaire
WO2024263798A1 (fr) Compositions comprenant des antinéoplastons et méthodes de traitement du cancer de la prostate
WO2024263804A2 (fr) Compositions comprenant des antinéoplastons et méthodes de traitement du cancer du rein
WO2024263960A2 (fr) Compositions comprenant des antinéoplastons et méthodes de traitement du cancer du poumon
EP4731793A2 (fr) Compositions comprenant des antinéoplastons et méthodes de traitement du cancer du pancréas
WO2024263972A2 (fr) Compositions comprenant des antinéoplastons et méthodes de traitement de cancers peu communs
EP4727534A1 (fr) Compositions comprenant des antinéoplastons et méthodes de traitement du cancer du sein
WO2024263963A2 (fr) Compositions comprenant des antinéoplastons et méthodes de traitement du cancer de la tête et du cou
JP2025508399A (ja) 脳がんの処置のためのニラパリブの使用
HK40094176A (zh) 用於治疗实体瘤的方法及包括krasg12c抑制剂和vegf抑制剂的组合物
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
HK40072142A (en) Quinoline derivative used for combination treatment of small cell lung cancer
Vasiliou 45TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2009

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260120

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR